ReviewDiscover oncology2025
Advances of androgen receptor in triple-negative breast cancer: from molecular mechanisms to clinical applications.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Genomic Alterations in Quadruple-Negative Breast Cancer Tumors.International journal of molecular sciences · 2026Article
- Matrix Stiffness Directs Stemness Signatures in Breast Cancer.Advanced healthcare materials · 2026Article
- Androgen Receptor Expression and T-Lymphocyte Infiltration as Prognostic Indicators in Triple-Negative Breast Cancer: A Retrospective Study.Biomedicines · 2026Article
- Review
- Bioactive Natural Compounds in Triple-Negative Breast Cancer: Molecular Targets and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Metronomic 5-Fluorouracil and Vinorelbine Reduce Cancer Stemness and Modulate EZH2/NOTCH-1/STAT3 Signaling in Triple-Negative Breast Cancer Spheroids.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) is a clinically aggressive malignancy with high heterogeneity at molecular and genetic levels, which characterized by the absence of effective therapeutic targets and marked resistance to conventional chemotherapy regimens. The androgen receptor (AR) is highly expressed by TNBC tumor cells and plays a vital role on tumor progression. With more research into AR signaling pathways and functions, AR-targeted therapy is becoming a promising treatment strategy. This review synthesizes emerging evidence in AR-related preclinical research and clinical outcomes, including monotherapy and combined strategies based on AR-targeted treatment. Through the comprehensive review, we hope to find novel therapeutic insights for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.